Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, announced it will host its 2026 capital markets day on September 8 at the London Stock Exchange, followed by an investor and analyst site visit in Slovenia on November 9-10. The events are designed to showcase the company's strategy for maximizing value in what it terms the 'golden decade for biosimilars.'
The capital markets day, which will be webcast live from 13:30 to 17:00 UK time, is open to investors and analysts. In-person attendance is by invitation only on a first-come, first-served basis. Details for accessing the live webcast are available at Sandoz's website. The site visit in Slovenia will provide further insight into the company’s new biosimilars development and supply-chain hub, though this event will not be webcast.
This announcement comes as Sandoz, which traces its heritage back to 1886, celebrates 20 years of pioneering biosimilars in 2026. The company’s portfolio includes approximately 1,300 medicines addressing diseases from the common cold to cancer. In 2025, Sandoz recorded net sales of USD 11.1 billion, highlighting its significant market presence.
The focus on biosimilars is critical for the pharmaceutical industry as patents on many biologic drugs expire, opening opportunities for more affordable alternatives. Biosimilars are highly similar to approved biologic drugs and can offer cost savings for healthcare systems. Sandoz's emphasis on this sector could impact patient access to essential medicines and healthcare costs globally.
Investors will be keen to understand Sandoz's growth strategy and how it plans to leverage its leadership position. The site visit in Slovenia, centered on the new biosimilars hub, underscores the company's investment in research and development capabilities. This could signal potential expansions in its product pipeline and manufacturing efficiencies.
The forward-looking statements in the press release caution that actual results may differ due to risks including global economic conditions, exchange rates, legal provisions, and competitive activities. Sandoz undertakes no obligation to revise these statements except as required by law.
For more information, contact Global Media Relations at Global.MediaRelations@sandoz.com or Investor Relations at Investor.Relations@sandoz.com.
